In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro discusses the advantages of their DiversImmune and MultiMab platforms for antibody discovery and engineering.

Guillain-Barré Syndrome occurs when the body’s immune system mistakenly attacks nerve cells, disrupting communication between ...